Login to Your Account



Federal Circuit Revisits Myriad Breast Cancer Gene Claims

By Mari Serebrov
Washington Editor

Monday, July 23, 2012
WASHINGTON – It was an encore performance in the Federal Circuit Friday as the panel of judges that ruled on the Association for Molecular Pathology v. Myriad Genetics Inc. last year listened to pretty much the same arguments about the patentability of isolated DNA all over again.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription